Dr. Rimawi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1504 Taub Loop
Houston, TX 77030Phone+1 713-873-8890Fax+1 713-798-8884
Education & Training
- Baylor College of MedicinePost-Doctoral Fellowship, 2003 - 2005
- Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004
- Baylor College of MedicineResidency, Internal Medicine, 1998 - 2001
- University of Jordan Faculty of MedicineClass of 1997
Certifications & Licensure
- TX State Medical License 2005 - 2026
- IN State Medical License 2004 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Neoadjuvant Herceptin in Patients With Breast Cancer Start of enrollment: 2001 Oct 01
- Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer Start of enrollment: 2003 Jan 01
- Neoadjuvant GW572016 to Treat Breast Cancer Start of enrollment: 2004 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 96 citationsHER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.Aleix Prat, Tomás Pascual, Carmine De Angelis, Carolina Gutierrez, Antonio Llombart-Cussac
Journal of the National Cancer Institute. 2020-01-01 - 352 citationsTamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic FunctionSuleiman Massarweh, C. Kent Osborne, Chad J. Creighton, Lanfang Qin, Anna Tsimelzon
Cancer Research. 2008-02-01 - 158 citationsEpidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.Mothaffar F. Rimawi, Priya B. Shetty, Heidi L. Weiss, Rachel Schiff, C. Kent Osborne
Cancer. 2010-03-01
Journal Articles
- The Oral Selective Oestrogen Receptor Degrader (SERD) AZD9496 Is Comparable to Fulvestrant in Antagonising ER and Circumventing Endocrine ResistanceRinath Jeselsohn, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff, Nature
Press Mentions
- Greenwich LifeSciences Provides Year End UpdateDecember 29th, 2022
- NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast CancerJune 14th, 2022
- Long-Term Repercussions of Postponing Care Due to COVID-19March 8th, 2021
- Join now to see all
Professional Memberships
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: